Sfoglia per AUTORE
POUR L
Collezione AO Cuneo

  

Items : 2

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. in The Lancet. Oncology / Lancet Oncol. 2023 Oct;24(10):1119-1133. doi: 10.1016/S1470-2045(23)00405-9. Epub 2023 Sep 14.

2023
AO Cuneo
AOU Città della Salute di Torino

Musto P; Boccadoro M; Gay F; Sonneveld P; Vangsted AJ; Benjamin R; Hájek R; Silkjaer T; Caers J; Zweegman S; Mancuso K; Razawy W; Tacchetti P; Offidani M; Grasso M; Giaccone L; van der Velden VHJ; Pour L; Lund T; Gadisseur A; Pietrantuono G; Roeloffzen WWH; Broijl A; Schjesvold F; Wu KL; van der Holt B; Minnema MC; van de Donk NWCJ;

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. in The Lancet. Haematology / Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.

2020
AOU Città della Salute di Torino
AO Cuneo

Sonneveld P; Boccadoro M; Carvalho S; Spencer A; Palmas A; Cafro AM; Minnema M; Mandigers C; van Marwijk Kooy M; Gimsing P; Mellqvist UH; Waage A; Driessen C; Specchia G; Zander T; Caravita di Toritto T; Durian M; von dem Borne PA; Hajek R; Wu KL; Boersma R; Morelli AM; Aquino S; Ludwig H; Levin MD; Bos G; Pascarella A; Benevolo G; Troia R; et alii...